Deuterium metabolic imaging (DMI) has emerged as a novel biomarker comparable to 18FDG PET by adding quantitative metabolic kinetic capabilities at high field (>3T). The main barrier for widespread clinical adoption, is the availability of high field clinical scanners. The aim of this study is to determine if DMI for neurological applications is feasible on a clinical 3T MRI scanner. Our findings suggests that it is indeed feasible, and that metabolic breakdown product (Glutamine/Glutamate) can be quantified around 120 min after ingestion.
This abstract and the presentation materials are available to members only; a login is required.